First-line immune checkpoint therapy in metastatic squamous cell lung cancer harboring both EGFR mutation and high expression of PD-L1: A case report

Kosuke Hamai; Hiroki Tanahashi; Sayaka Ueno; Hanae Konishi; Mirai Matsumura; Akio Nomura; Kanako Nakamoto; Shoko Isoyama; Takuya Tanimoto; Hiroyasu Shoda; Nobuhisa Ishikawa

doi:10.1111/1759-7714.13436

First-line immune checkpoint therapy in metastatic squamous cell lung cancer harboring both EGFR mutation and high expression of PD-L1: A case report

Thorac Cancer. 2020 Jun;11(6):1716-1719. doi: 10.1111/1759-7714.13436. Epub 2020 Apr 14.

Authors

Affiliations

¹ Department of Respiratory Medicine, Hiroshima Prefectural Hospital, Hiroshima, Japan.
² Department of Internal and Molecular Medicine, Hiroshima University, Hiroshima, Japan.
³ Department of Respiratory Medicine, Hiroshima City Asa Citizens Hospital, Hiroshima, Japan.
⁴ Department of Respiratory Medicine, Hiroshima City Funairi Citizens Hospital, Hiroshima, Japan.
⁵ Department of Respiratory Medicine, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan.

Abstract

A 90-year-old female was admitted to our hospital with a history of a dry cough. Chest computed tomography (CT) scan showed a tumor shadow, and CT-guided lung biopsy revealed squamous cell carcinoma harboring an EGFR mutation. In addition, programmed death-ligand 1 (PD-L1) was highly expressed with a tumor proportion score (TPS) of >75%. Pembrolizumab therapy in the first-line setting was not effective, and the patient died at six months from the first visit. Squamous cell lung cancers (SCLCs) with both EGFR mutation and high expression of PD-L1 are very rare.

Keywords: Epidermal growth factor receptor (EGFR) mutation; pembrolizumab; programmed death-ligand 1 (PD-L1); squamous cell lung cancer.

Publication types

Case Reports

MeSH terms

Aged, 80 and over
Antibodies, Monoclonal, Humanized / therapeutic use*
Antineoplastic Agents, Immunological / therapeutic use
B7-H1 Antigen / metabolism*
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / genetics
Carcinoma, Non-Small-Cell Lung / immunology
Carcinoma, Non-Small-Cell Lung / pathology
Carcinoma, Squamous Cell / drug therapy*
Carcinoma, Squamous Cell / genetics
Carcinoma, Squamous Cell / immunology
Carcinoma, Squamous Cell / secondary
ErbB Receptors / genetics
Fatal Outcome
Female
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / genetics
Lung Neoplasms / immunology
Lung Neoplasms / pathology
Mutation*

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
B7-H1 Antigen
CD274 protein, human
pembrolizumab
EGFR protein, human
ErbB Receptors